| Mulpleta (lusutrombopag) / Shionogi |
NCT06426043: A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag |
|
|
| Not yet recruiting | 4 | 40 | RoW | Lusutrombopag | Peking Union Medical College Hospital | Aplastic Anemia | 06/25 | 08/25 | | |
| Recruiting | 4 | 17 | | Lusutrombopag | Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, None | Primary immune thrombocytopenia | | | | |
ChiCTR2400084012: Efficacy and safety of lusutrombopag in the treatment of patients with non-severe aplastic anemia (NSAA). |
|
|
| Not yet recruiting | 4 | 15 | | Lusutrombopag. | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, None | Adult patients with non-severe aplastic anemia | | | | |
ChiCTR2400084748: Clinical study on the efficacy and safety of lusutrombopag in the treatment of thrombocytopenia in patients undergoing liver resection after conversion therapy for liver cancer |
|
|
| Not yet recruiting | 4 | 120 | | Oral medication (3mg/ day) for 7 consecutive days; Blank control | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Sichuan Provincial Medical Science and Technology Innovation Research Association | Hepatocellular carcinoma associated thrombocytopenia | | | | |
NCT06287567: Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 2 | 17 | RoW | Lusutrombopag Oral Tablet, MULPLETA®, S-888711 | Institute of Hematology & Blood Diseases Hospital, China | Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | 09/24 | 11/24 | | |